Clinical Trials Logo

Unresectable clinical trials

View clinical trials related to Unresectable.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05449483 Recruiting - Unresectable Clinical Trials

Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma

Start date: May 11, 2022
Phase: Phase 2
Study type: Interventional

Whether the introduction of immunotherapy can transform unresectable esophageal cancer into resectable, or even achieve R0 surgical resection, has not been reported yet. We plan to conduct a prospective, single-center, single-arm phase II clinical study of the safety and efficacy of tislelizumab combined with chemotherapy in the treatment of unresectable esophageal squamous cell carcinoma.